PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Ulcerative colitis

Drugs in development · updated 30 October 2026

Ulcerative colitis: drugs in development

As of 30 October 2026 there are 116 active clinical trials (recruiting or ongoing, phases I–III) on 99 drugs for ulcerative colitis. 66 are experimental, that is not yet approved in the United States.

116Active trials
66Experimental drugs
6Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
DuvakitugIII2NCT07184996
JNJ-78934804III2NCT07577856
ObefazimodABX464III2NCT05535946
TulisokibartIII2NCT06651281
FilgotinibJyseleca®III1NCT06865417
Hemay005III1NCT07650942
AquaminII2NCT07501078
BRS201II2NCT06420375
LY4268989II2NCT07186101
SPY001II2NCT07652294
SPY002II2NCT07652294
SPY003II2NCT07652294
ZasocitinibTAK-279II2NCT06254950
ABBV-701II1NCT07697456
AC-101II1NCT07755241
Adalimumab-680LTI–II1NCT07258641
ALTB-268II1NCT06109441
ATH-063II1NCT07513181
Baitouweng TangII1NCT06421818
D-2570II1NCT07035041
EltrekibartII1NCT06598943
EmvistegrastII1NCT06290934
HSK47388II1NCT07335055
ICG318I–II1NCT07544160
IL-15I–II1NCT07544160
INT-210I–II1NCT07692165
ISM5411II1NCT07265570
LutikizumabII1NCT06257875
LY4395089II1NCT07483073
MB-001I–II1NCT07374471
MH002II1NCT07296315
MK-8690II1NCT07463183
MT-201II1NCT07113522
MT-501II1NCT07113522
OD-07656II1NCT06850727
PALI-2108II1NCT07845487
PL8177II1NCT05466890
PTT-621II1NCT07747155
RO7837195II1NCT06979336
RosnilimabII1NCT06127043

Sorted by most advanced phase and number of active trials. Showing 40 of 66 drugs.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
GuselkumabTremfyaII–III6NCT04033445
MirikizumabOmvoh®III6NCT06937086
VedolizumabEntyvio®III6NCT06405087
RisankizumabSKYRIZIIII5NCT07071519
EtrasimodVelsipity®III3NCT03950232
InfliximabZymfentra®, Avsola®III3NCT03596645
UpadacitinibRinvoq Lq®, Rinvoq®III3NCT05782907
UstekinumabPyzchiva®, Starjemza®III3NCT05092269
GolimumabImmgolis®, Immgolis Intri®III2NCT03596645
ModafinilProvigil®II–III2NCT07582458
NitazoxanideAlinia®II–III2NCT07820046
IcotrokinraIcotyde®III1NCT07196748
OzanimodZeposia®II–III1NCT05076175
PonesimodPonvory®III1NCT07686081
PrednisonePredinisone, CortancylII–III1NCT03804931

Sorted by most advanced phase and number of active trials. Showing 15 of 33 drugs.

All 99 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D003093 “Colitis, Ulcerative”.

ItalianoFrançaisDeutsch